Menu
Menu
Eris Lifesciences vends the entire interest it holds in the deadweight of two components for Therapeutics Ltd. to Eris for Rs 861.9 crore, thus connecting up with its core business growth, which is a strategic focus.
Pfizer and Mylan have formed a strategic marketing and supply partnership for two key medications, Ativan and Pacitane. This collaboration aims to expand global access to treatments for anxiety disorders and Parkinsonism, ensuring broader availability for patients in need.
Lupin and Natco Pharma have received USFDA approval for Bosentan Tablets for Oral Suspension, a generic treatment for pediatric patients with pulmonary arterial hypertension (PAH). This approval provides an affordable option for improving exercise capacity and quality of life for children suffering from PAH.
Sun Pharmaceutical Industries has posted a strong 15% year-on-year growth in net profit for Q3 FY2025, reaching Rs 2,903 crore. With robust sales across key markets, including the US and emerging regions, the company’s diversified portfolio and strategic product launches are driving its continued success. Explore how Sun Pharma’s growth strategy is positioning it for sustained leadership in the global pharmaceutical industry.
Strides Pharma Science delivered impressive results for Q3 FY2024, with net profit soaring 77% to Rs 87.95 crore and sales growing 14.71%. This growth highlights the company’s operational efficiency and strong market positioning.
Piramal Pharma has launched Chlorpromazine Hydrochloride for Injection in the U.S., enhancing its critical care portfolio. This new generic product offers an affordable solution for treating psychiatric disorders such as schizophrenia, paranoia, and mania, marking another key milestone in the company's growth in the injectables market.
Alembic Pharmaceuticals has secured USFDA approval for its generic version of Brexpiprazole Tablets, a treatment for major depressive disorder and schizophrenia. This approval opens the door to a $2 billion market, providing a more affordable option for patients while strengthening Alembic’s position in the generics sector.
Mankind Pharma has joined forces with Innovent Biologics to bring Sintilimab, a cutting-edge cancer immunotherapy, to India. This exclusive partnership aims to improve access to advanced cancer treatments in India, with plans for regulatory approval and clinical trials set to begin in 2025.
Aurobindo Pharma's Telangana facility recently underwent an FDA inspection, resulting in two procedural observations. While these observations are not related to product quality, the company plans to address them promptly. In the meantime, Aurobindo continues to show strong financial performance, driven by sales growth in key markets like Europe and the U.S.
Mankind Pharma’s stock surged following the announcement of a Qualified Institutional Placement (QIP) at a floor price of Rs 2,616.55 per share, aiming to raise up to Rs 3,000 crore. This move is expected to support the company’s expansion and growth, both in India and internationally.